Polymed was founded by industry veterans with a vision to create new and better medicines by leveraging cutting technologies. We strive to create novel therapeutics for oncology and auto-immune diseases with unmet needs. Building on our deep expertise in AI-assisted design and medicinal chemistry including proteolysis-targeting chimeras (PROTAC) and drug-antibody conjugate (DAC), we have developed proprietary platform technology that enables us to tackle traditionally undruggable disease drivers. With a streamlined portfolio, we are rapidly advancing first- and best- in-class medicines into clinical testing.